AstraZeneca is utilizing platinum-based chemotherapy in ongoing clinical trials.
4 reports, 1 independent
Updated Aug 19
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca is utilizing platinum-based chemotherapy in ongoing clinical trials.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
platinum
chemical element with symbol Pt and atomic number 78
Related events
- AstraZeneca's drug was tested in collaboration with Pfizer's drug.
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Joint drug trial success boosts Amgen stock.
- A drug status update affecting Australian patients involves Ipsen and AstraZeneca, with changes made to the Pharmaceutical Benefits Scheme (PBS) on September 1, 2026.
- Petra Hamerlik, who previously worked at AstraZeneca plc, has been appointed as the Chair of Translational Neuro-Oncology at the University of Manchester.
Coverage
Newest first; wire copies grouped- Business WireTAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer Longer-term follow up i